What is the Share Price of Ipca Laboratories Ltd?
- Answer Field
-
The share price of Ipca Laboratories Ltd for NSE is ₹ 1407 and for BSE is ₹ 1399.
BAJAJ BROKING
As of the latest trading session, Ipca Laboratories Ltd share price is currently at 1407, which is up by 39.00 from its previous closing. Today, the stock has fluctuated between 1352.30 and 1425.00. Over the past year, Ipca Laboratories Ltd has achieved a return of 3.03 %. In the last month alone, the return has been 3.81 %. Read More...
1633
524494
IPCALAB
Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.
(Standalone)
Market Cap (Cr) | 35696.18 |
PE Ratio (TTM) | 44.33 |
Book Value / Share | 265.60 |
Beta | 0.69 |
ROE | 9.81% |
EPS (TTM) | 32.66 |
Dividend Yield | 0.29% |
Net Profit Qtr (Cr) | 267.56 |
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 1662.68 |
Operating Expense | 1324.57 |
Net Profit | 267.56 |
Net Profit Margin (%) | 16.09 |
Earnings Per Share (EPS) | 10.55 |
EBITDA | 428.50 |
Effective Tax Rate (%) | 24.74 |
Particulars | SEP 2024 (Values in Cr) |
---|---|
Revenue | 1810.94 |
Operating Expense | 1488.73 |
Net Profit | 244.12 |
Net Profit Margin (%) | 13.48 |
Earnings Per Share (EPS) | 9.62 |
EBITDA | 419.10 |
Effective Tax Rate (%) | 28.03 |
Particulars | JUN 2024 (Values in Cr) |
---|---|
Revenue | 1565.86 |
Operating Expense | 1293.36 |
Net Profit | 204.13 |
Net Profit Margin (%) | 13.03 |
Earnings Per Share (EPS) | 8.05 |
EBITDA | 368.63 |
Effective Tax Rate (%) | 29.09 |
Particulars | MAR 2024 (Values in Cr) |
---|---|
Revenue | 1510.62 |
Operating Expense | 1304.10 |
Net Profit | 64.76 |
Net Profit Margin (%) | 4.28 |
Earnings Per Share (EPS) | 2.55 |
EBITDA | 213.11 |
Effective Tax Rate (%) | 49.12 |
Particulars | DEC 2023 (Values in Cr) |
---|---|
Revenue | 1506.82 |
Operating Expense | 1324.01 |
Net Profit | 136.94 |
Net Profit Margin (%) | 9.08 |
Earnings Per Share (EPS) | 5.40 |
EBITDA | 290.38 |
Effective Tax Rate (%) | 31.58 |
Particulars | MAR 2024 (Values in Cr) |
---|---|
Revenue | 6166.46 |
Operating Expense | 5322.23 |
Net Profit | 530.41 |
Net Profit Margin (%) | 8.60 |
Earnings Per Share (EPS) | 20.91 |
EBITDA | 1189.31 |
Effective Tax Rate (%) | 35.48 |
Particulars | MAR 2023 (Values in Cr) |
---|---|
Revenue | 5814.62 |
Operating Expense | 5175.32 |
Net Profit | 505.70 |
Net Profit Margin (%) | 8.69 |
Earnings Per Share (EPS) | 19.93 |
EBITDA | 1023.04 |
Effective Tax Rate (%) | 32.61 |
Particulars | MAR 2022 (Values in Cr) |
---|---|
Revenue | 5438.30 |
Operating Expense | 4417.11 |
Net Profit | 860.37 |
Net Profit Margin (%) | 15.82 |
Earnings Per Share (EPS) | 33.91 |
EBITDA | 1291.00 |
Effective Tax Rate (%) | 19.89 |
Particulars | MAR 2021 (Values in Cr) |
---|---|
Revenue | 5139.16 |
Operating Expense | 3821.44 |
Net Profit | 1140.77 |
Net Profit Margin (%) | 22.19 |
Earnings Per Share (EPS) | 90.08 |
EBITDA | 1575.82 |
Effective Tax Rate (%) | 17.33 |
Particulars | MAR 2020 (Values in Cr) |
---|---|
Revenue | 4367.43 |
Operating Expense | 3647.15 |
Net Profit | 652.46 |
Net Profit Margin (%) | 14.93 |
Earnings Per Share (EPS) | 51.64 |
EBITDA | 979.45 |
Effective Tax Rate (%) | 16.88 |
Particulars | MAR 2024 (Values in Cr) |
---|---|
Book Value / Share | 249.59 |
ROE % | 8.69 |
ROCE % | 12.92 |
Total Debt to Total Equity | 0.24 |
EBITDA Margin | 17.40 |
Particulars | MAR 2023 (Values in Cr) |
---|---|
Book Value / Share | 230.27 |
ROE % | 8.70 |
ROCE % | 11.59 |
Total Debt to Total Equity | 0.20 |
EBITDA Margin | 16.90 |
Particulars | MAR 2022 (Values in Cr) |
---|---|
Book Value / Share | 215.41 |
ROE % | 17.92 |
ROCE % | 20.26 |
Total Debt to Total Equity | 0.11 |
EBITDA Margin | 23.66 |
Particulars | MAR 2021 (Values in Cr) |
---|---|
Book Value / Share | 370.65 |
ROE % | 27.59 |
ROCE % | 30.56 |
Total Debt to Total Equity | 0.09 |
EBITDA Margin | 29.71 |
Particulars | MAR 2020 (Values in Cr) |
---|---|
Book Value / Share | 286.15 |
ROE % | 17.88 |
ROCE % | 19.51 |
Total Debt to Total Equity | 0.14 |
EBITDA Margin | 20.85 |
Particulars | MAR 2024 (Values in Cr) |
---|---|
Book Value / Share | 250.24 |
ROE % | 9.81 |
ROCE % | 14.12 |
Total Debt to Total Equity | 0.21 |
EBITDA Margin | 21.08 |
Particulars | MAR 2023 (Values in Cr) |
---|---|
Book Value / Share | 231.66 |
ROE % | 8.91 |
ROCE % | 11.67 |
Total Debt to Total Equity | 0.20 |
EBITDA Margin | 17.64 |
Particulars | MAR 2022 (Values in Cr) |
---|---|
Book Value / Share | 215.84 |
ROE % | 16.82 |
ROCE % | 19.15 |
Total Debt to Total Equity | 0.10 |
EBITDA Margin | 23.80 |
Particulars | MAR 2021 (Values in Cr) |
---|---|
Book Value / Share | 374.67 |
ROE % | 27.06 |
ROCE % | 30.20 |
Total Debt to Total Equity | 0.08 |
EBITDA Margin | 30.72 |
Particulars | MAR 2020 (Values in Cr) |
---|---|
Book Value / Share | 290.11 |
ROE % | 19.15 |
ROCE % | 20.63 |
Total Debt to Total Equity | 0.13 |
EBITDA Margin | 22.50 |
Particulars | MAR 2024 (Values in Cr) |
---|---|
Cash & Short Term Investments | 296.84 |
Total Assets | 11101.28 |
Total Liabilities | 11101.28 |
Total Equity | 7727.00 |
Share Outstanding | 253704218 |
Price to Book Ratio | 4.95 |
Return on Assets (%) | 4.93 |
Return on Capital (%) | 6.01 |
Particulars | MAR 2023 (Values in Cr) |
---|---|
Cash & Short Term Investments | 1853.24 |
Total Assets | 8626.43 |
Total Liabilities | 8626.43 |
Total Equity | 5915.32 |
Share Outstanding | 253704218 |
Price to Book Ratio | 3.50 |
Return on Assets (%) | 5.46 |
Return on Capital (%) | 6.39 |
Particulars | MAR 2022 (Values in Cr) |
---|---|
Cash & Short Term Investments | 640.66 |
Total Assets | 7623.53 |
Total Liabilities | 7623.53 |
Total Equity | 5541.76 |
Share Outstanding | 253704218 |
Price to Book Ratio | 4.92 |
Return on Assets (%) | 11.59 |
Return on Capital (%) | 13.96 |
Particulars | MAR 2021 (Values in Cr) |
---|---|
Cash & Short Term Investments | 365.07 |
Total Assets | 6068.36 |
Total Liabilities | 6068.36 |
Total Equity | 4716.18 |
Share Outstanding | 126852109 |
Price to Book Ratio | 5.08 |
Return on Assets (%) | 18.78 |
Return on Capital (%) | 22.94 |
Particulars | MAR 2020 (Values in Cr) |
---|---|
Cash & Short Term Investments | 180.92 |
Total Assets | 5259.83 |
Total Liabilities | 5259.83 |
Total Equity | 3641.11 |
Share Outstanding | 126352109 |
Price to Book Ratio | 4.78 |
Return on Assets (%) | 11.52 |
Return on Capital (%) | 14.95 |
Particulars | MAR 2024 (Values in Cr) |
---|---|
Cash & Short Term Investments | 112.92 |
Total Assets | 8659.27 |
Total Liabilities | 8659.27 |
Total Equity | 6348.71 |
Share Outstanding | 253704218 |
Price to Book Ratio | 4.95 |
Return on Assets (%) | 6.12 |
Return on Capital (%) | 7.09 |
Particulars | MAR 2023 (Values in Cr) |
---|---|
Cash & Short Term Investments | 1706.06 |
Total Assets | 8446.97 |
Total Liabilities | 8446.97 |
Total Equity | 5877.30 |
Share Outstanding | 253704218 |
Price to Book Ratio | 3.50 |
Return on Assets (%) | 5.98 |
Return on Capital (%) | 6.93 |
Particulars | MAR 2022 (Values in Cr) |
---|---|
Cash & Short Term Investments | 595.50 |
Total Assets | 7438.44 |
Total Liabilities | 7438.44 |
Total Equity | 5475.76 |
Share Outstanding | 253704218 |
Price to Book Ratio | 4.92 |
Return on Assets (%) | 11.56 |
Return on Capital (%) | 13.8 |
Particulars | MAR 2021 (Values in Cr) |
---|---|
Cash & Short Term Investments | 306.92 |
Total Assets | 6010.13 |
Total Liabilities | 6010.13 |
Total Equity | 4752.72 |
Share Outstanding | 126852109 |
Price to Book Ratio | 5.08 |
Return on Assets (%) | 18.98 |
Return on Capital (%) | 22.93 |
Particulars | MAR 2020 (Values in Cr) |
---|---|
Cash & Short Term Investments | 152.40 |
Total Assets | 5184.57 |
Total Liabilities | 5184.57 |
Total Equity | 3677.54 |
Share Outstanding | 126352109 |
Price to Book Ratio | 4.78 |
Return on Assets (%) | 12.58 |
Return on Capital (%) | 16.05 |
Particulars | MAR 2024 (Values in Cr) |
---|---|
Net Income | 842.67 |
Cash from Operations | 1240.95 |
Cash from Investing | -1291.79 |
Cash from Financing | -552.55 |
Net change in Cash | -899.69 |
Free Cash Flow | 1651.55 |
Particulars | MAR 2023 (Values in Cr) |
---|---|
Net Income | 745.29 |
Cash from Operations | 1029.46 |
Cash from Investing | -725.00 |
Cash from Financing | 507.24 |
Net change in Cash | 588.05 |
Free Cash Flow | 1523.93 |
Particulars | MAR 2022 (Values in Cr) |
---|---|
Net Income | 1135.72 |
Cash from Operations | 1058.11 |
Cash from Investing | -855.05 |
Cash from Financing | 426.78 |
Net change in Cash | 427.80 |
Free Cash Flow | 1537.06 |
Particulars | MAR 2021 (Values in Cr) |
---|---|
Net Income | 1388.98 |
Cash from Operations | 1335.72 |
Cash from Investing | -520.69 |
Cash from Financing | -305.82 |
Net change in Cash | 263.62 |
Free Cash Flow | 1697.27 |
Particulars | MAR 2020 (Values in Cr) |
---|---|
Net Income | 738.89 |
Cash from Operations | 722.57 |
Cash from Investing | -509.65 |
Cash from Financing | -136.54 |
Net change in Cash | -75.84 |
Free Cash Flow | 1028.85 |
Particulars | MAR 2024 (Values in Cr) |
---|---|
Net Income | 822.16 |
Cash from Operations | 1107.46 |
Cash from Investing | -1355.18 |
Cash from Financing | -464.88 |
Net change in Cash | -989.55 |
Free Cash Flow | 1467.68 |
Particulars | MAR 2023 (Values in Cr) |
---|---|
Net Income | 750.49 |
Cash from Operations | 977.54 |
Cash from Investing | -709.61 |
Cash from Financing | 506.38 |
Net change in Cash | 559.06 |
Free Cash Flow | 1414.40 |
Particulars | MAR 2022 (Values in Cr) |
---|---|
Net Income | 1074.11 |
Cash from Operations | 1023.88 |
Cash from Investing | -814.00 |
Cash from Financing | 426.04 |
Net change in Cash | 443.76 |
Free Cash Flow | 1475.51 |
Particulars | MAR 2021 (Values in Cr) |
---|---|
Net Income | 1379.96 |
Cash from Operations | 1337.93 |
Cash from Investing | -559.56 |
Cash from Financing | -307.38 |
Net change in Cash | 229.12 |
Free Cash Flow | 1687.58 |
Particulars | MAR 2020 (Values in Cr) |
---|---|
Net Income | 784.97 |
Cash from Operations | 707.84 |
Cash from Investing | -499.13 |
Cash from Financing | -138.67 |
Net change in Cash | -76.37 |
Free Cash Flow | 980.91 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 39.03 | 20.98 | 2.13 | 299.10 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 124.20 | 16.28 | 1.29 | 1308.70 | 92.25 / 184.95 |
CIPLA LTD | 1481.40 | 23.98 | 4.21 | 119640.40 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 275.45 | 22.82 | 2.79 | 810.68 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 39.03 | 23.51 | 6.63 | 299.10 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 671.60 | 39.37 | 6.52 | 1941.64 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8871.70 | 132.31 | 32.64 | 22179.25 | 5000.00 / 9049.95 |
BLISS GVS PHARMA LTD | 124.20 | 16.13 | 1.27 | 1308.70 | 92.25 / 184.95 |
First Resistance | 1390.20 |
Second Resistance | 1412.40 |
Third Resistance | 1449.00 |
First Support | 1331.40 |
Second Support | 1294.80 |
Third Support | 1272.60 |
RSI | 48.04 |
MACD | -15.65 |
Commodity Channel Index (CCI) | -39.40 |
ADX | 34.65 |
Williams % R | -42.41 |
Name | Category | Shares | Shares% |
---|---|---|---|
Kaygee Investments Private Limited | Shareholding of Promoter and Promoter Group | 5.447839E7 | 21.47 |
Hdfc Mutual Fund - Hdfc Mid-cap Opportunities Fund | Public Shareholding | 2.148117E7 | 8.47 |
Kaygee Laboratories Private Limited | Shareholding of Promoter and Promoter Group | 1.677E7 | 6.61 |
Dsp Midcap Fund | Public Shareholding | 1.5708204E7 | 6.19 |
Kotak Emerging Equity Scheme | Public Shareholding | 1.4688543E7 | 5.79 |
Chandurkar Investments Private Limited | Shareholding of Promoter and Promoter Group | 1.395601E7 | 5.5 |
Paschim Chemicals Pvt Ltd | Shareholding of Promoter and Promoter Group | 1.0173E7 | 4.01 |
Sbi Life Insurance Co. Ltd | Public Shareholding | 7226128.0 | 2.85 |
Premchand Godha | Shareholding of Promoter and Promoter Group | 5814680.0 | 2.29 |
Nippon Life India Trustee Ltd-a/c Nippon India Growth Fund | Public Shareholding | 5705808.0 | 2.25 |
Hdfc Life Insurance Company Limited | Public Shareholding | 4899684.0 | 1.93 |
Usha M Chandurkar | Shareholding of Promoter and Promoter Group | 4302000.0 | 1.7 |
Kotak Funds - India Midcap Fund | Public Shareholding | 3274433.0 | 1.29 |
Usha Premchand Godha | Shareholding of Promoter and Promoter Group | 2418740.0 | 0.95 |
Sameer M Chandurkar | Shareholding of Promoter and Promoter Group | 2000000.0 | 0.79 |
Pranay Godha | Shareholding of Promoter and Promoter Group | 1700990.0 | 0.67 |
Prashant Godha | Shareholding of Promoter and Promoter Group | 1568644.0 | 0.62 |
Kalpana Jain | Shareholding of Promoter and Promoter Group | 230000.0 | 0.09 |
Mexin Medicaments Private Limited | Shareholding of Promoter and Promoter Group | 14058.0 | 0.01 |
Xbees Traders Llp | Shareholding of Promoter and Promoter Group | 31000.0 | 0.01 |
Makers Laboratories Limited | Shareholding of Promoter and Promoter Group | 960.0 | 0.0 |
Nirmal Jain | Shareholding of Promoter and Promoter Group | 0.0 | 0.0 |
Neetu Godha | Shareholding of Promoter and Promoter Group | 4000.0 | 0.0 |
Bhawna Godha | Shareholding of Promoter and Promoter Group | 5000.0 | 0.0 |
Ex-Date | Dividend Amt. | Dividend Type | Record Date | Instrument Type | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-22 | 2.0 | Interim | 2023-11-22 | Equity shares | 2022-11-22 | 4.0 | Interim | 2022-11-23 | Equity shares | 2021-11-22 | 8.0 | Interim | 2021-11-23 | Equity shares | 2020-11-13 | 8.0 | Interim | 2020-11-17 | Equity shares | 2020-02-18 | 5.0 | Interim | 2020-02-20 | Equity shares | 2019-08-06 | 3.0 | Final | 2019-08-08 | Equity shares | 2018-08-02 | 1.0 | Final | 2018-08-04 | Equity shares | 2017-07-27 | 1.0 | Final | 2017-07-29 | Equity shares | 2015-07-22 | 1.0 | Final | 2015-07-24 | Equity shares | 2014-07-18 | 2.5 | Final | 2014-07-22 | Equity shares | 2013-10-31 | 2.5 | Interim | 2013-11-01 | Equity shares | 2013-07-19 | 2.0 | Final | 2013-07-23 | Equity shares | 2012-11-01 | 2.0 | Interim | 2012-11-02 | Equity shares | 2012-07-20 | 1.2 | Final | 2012-07-24 | Equity shares | 2012-02-07 | 1.0 | Interim 2 | 2012-02-08 | Equity shares | 2011-11-03 | 1.0 | Interim | 2011-11-07 | Equity shares | 2011-07-18 | 1.2 | Final | 2011-07-20 | Equity shares | 2011-02-01 | 1.0 | Interim 2 | 2011-02-02 | Equity shares | 2010-10-28 | 1.0 | Interim | 2010-10-29 | Equity shares | 2010-07-16 | 1.0 | Final | 2010-07-20 | Equity shares | 2010-01-27 | 4.0 | Interim 2 | 2010-01-28 | Equity shares | 2009-10-30 | 5.0 | Interim | 2009-11-03 | Equity shares | 2009-07-20 | 4.0 | Final | 2009-07-22 | Equity shares | 2009-01-27 | 3.0 | Interim 2 | 2009-01-28 | Equity shares | 2008-11-07 | 4.0 | Interim | 2008-11-10 | Equity shares | 2008-07-14 | 4.5 | Final | 2008-07-16 | Equity shares | 2007-11-06 | 3.5 | Interim | 2007-11-07 | Equity shares | 2007-07-10 | 4.0 | Final | 2007-07-12 | Equity shares | 2006-11-02 | 3.5 | Interim | 0001-01-01 | Equity shares | 2005-11-09 | 0.0 | Interim | 2005-11-10 | Equity shares | 2005-09-13 | 0.0 | Final | 2005-09-15 | Equity shares |
Ex-Date | Ex-Bonus | Ratio |
---|---|---|
2005-01-31 | 2005-01-28 | 1:1 |
Ex-Date | Old FV | NEW FV | Record Date | ||||
---|---|---|---|---|---|---|---|
2022-01-10 | 2.0 | 1.0 | 2022-01-11 | 2010-03-22 | 10.0 | 2.0 | 2010-03-23 |
The share price of Ipca Laboratories Ltd for NSE is ₹ 1407 and for BSE is ₹ 1399.
The market cap of Ipca Laboratories Ltd for NSE is ₹ 3,56,96.18 Cr. and for BSE is ₹ 3,54,93.22 Cr. as of now.
The 52 Week High and Low of Ipca Laboratories Ltd for NSE is ₹ 1755.90 and ₹ 1052.00 and for BSE is ₹ 1757.65 and ₹ 1060.95.
You can trade in Ipca Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 3.03%.
Ipca Laboratories Ltd share price is for NSE ₹ 1407 & for BSE ₹ 1399 as on Apr 16 2025 03:29 PM.
The market cap of Ipca Laboratories Ltd for NSE ₹ 3,56,96.18 & for BSE ₹ 3,54,93.22 as on Apr 16 2025 03:29 PM.
As on Apr 16 2025 03:29 PM the price-to-earnings (PE) ratio for Ipca Laboratories Ltd share is 44.33.
As on Apr 16 2025 03:29 PM, the price-to-book (PB) ratio for Ipca Laboratories Ltd share is 265.60.
You can trade in Ipca Laboratories Ltd shares with Bajaj Broking by opening a demat accountopens in a new tab.
To buy Ipca Laboratories Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Ipca Laboratories Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading
TRENDING CALCULATORS AND STOCKS ON BAJAJ BROKING
POPULAR STOCKS: Tata Motors Share Price Infosys Share Price IRFC Share Price SBI Card Share Price Cipla Share Price NBCC Share Price IDFC First Bank Share Price IRCTC Share Price PNB Share Price Vodafone Idea Share Price Axis Bank Share Price JSW Steel Share Price Bandhan Bank Share Price SBI Share Price Tata Steel Share Price ONGC Share Price Ashok Leyland Share Price Paytm Share Price Subex Share Price DLF Share Price Reliance Share Price HDFC Bank Share Price Suzlon Share Price IOC Share Price HUL Share Price Asian Paints Share Price Bank Of Baroda Share Price ITC Share Price TCS Share Price HFCL Share Price Icici Bank Share Price Tata Chemicals Share Price CDSI Share Price MRF Share Price Tata Power Share Price Adani Green share price BPCL Share Price Vedanta Share Price Dmart Share Price Hindalco Share Price LIC Share Price SAIL Share Price Adani Port Share Price IEX Share Price Nalco Share Price L&T Share Price Adani Power Share Price BHEL Share Price Bajaj Finance Share Price Canara Bank Share Price Indusind Bank Share Price Gail Share Price Yes Bank Share Price Wipro Share Price Happiest Minds Share Price Coal India Share Price Maruti Share Price Reliance Power Share Price
INDIAN INDICES: Nifty 50 Share Price SENSEX Share Price Nifty Next 50 Share Price BSE100 Share Price Nifty Bank Share Price LRGCAP Share Price Nifty 100 Share Price MIDCAP Share Price Nifty 200 Share Price SMLCAP Share Price Nifty 500 Share Price BSE500 Share Price Nifty Midcap 50 Share Price ALLCAP Share Price NIFTY SMLCAP 50 Share Price BSE200 Share Price India VIX Share Price BSEIPO Share Price
“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."
"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."
" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."
"KYC...